Relationship Between Albumin to Fibrinogen Ratio and Different Stages of Cervical Cancer in a Tertiary Care Center

Author(s): Dr. Moushume Akther Liza, Dr. Rowson Ara, Dr. Sunzia Sayed, Dr. Asma Akter Sonia, Dr. Jannatul Islam, Dr. Tahsin Zaman, Dr. Shabnom Mostofa Purobi

Introduction:

Cervical cancer is a significant global health concern, being the fourth most common cancer and leading cause of cancer death in women. Therefore, the purpose of this study was to determine the relationship of albumin-to-fibrinogen ratio in different stages of cervical cancer.

Aim of the study:

The aim of the study was to assess the relationship between pretreatment albumin-to-fibrinogen ratio (AFR) and the stages of cervical cancer in a tertiary care center.

Methods:

This cross-sectional analytical study, conducted at the Department of Gynecological Oncology, BSMMU, Dhaka, from July 2022 to June 2023, included 70 women with biopsy-confirmed cervical cancer, categorized into early-stage (IA-IIA) and advanced-stage (IIB-IV) groups. Data were collected using a semi-structured questionnaire and included socio-demographic and clinical variables, with analyses performed using SPSS version 27.0 to evaluate the relationship between cervical cancer stages and various factors.

Result:

Nearly half (47.1%) of respondents were aged 30–44, with a mean age of 45.37 ± 9.54 years; 84.3% were housewives. About 44.3% were in FIGO stage I, and 50% had advanced-stage cancer. The mean AFR was 10.26 ± 1.47, decreasing significantly with higher stages. A negative correlation (rs = -0.421, p < 0.001) showed AFR < 10.7 raised the odds of advanced cancer by 10.2 times (OR = 10.154, p < 0.001).

Conclusion:

AFR decreases with advancing cervical cancer stages, showing potential as a predictive biomarker, with patients having AFR <10.7 being 10.2 times more likely to present with advanced-stage disease.